Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome
Cancers · 04.06.2026 · 18 (11) · 1836
DOI: 10.3390/cancers18111836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 04.06.2026. Verfasst von Meridith L Balbach und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Department of Defense, NIH.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) can induce a sicca-like syndrome that differs from primary Sjögren’s disease in both immunopathogenesis and clinical phenotype. Despite growing recognition of this entity, data describing real-world management and outcomes, particularly in the context of ICI discontinuation and rechallenge, remain limited.
Methods
Patients with new onset of sicca syndrome or exacerbation of previous symptoms following ICI therapy were retrospectively identified and assessed.
Results
Fifty-nine patients with diverse malignancies (including melanoma, gastrointestinal, genitourinary, etc.) and sicca syndrome following treatment with ICIs (most often pembrolizumab or nivolumab +/− ipilimumab) were evaluated. Acute-onset dry mouth, primarily CTCAE v6.0 grades 1 (n = 24, 40.7%) and 2 (n = 34, 57.6%), occurred at a median of 104 days after ICI initiation, sometimes with associated dry eye (n = 8, 13.6%). Most were managed conservatively with behavioral modification and over-the-counter therapies alone (n = 37, 62.7%) while others received sialagogues (n = 9, 15.3%), dexamethasone oral rinse (n = 11, 18.6%), and/or systemic corticosteroids (n = 16, 27.1%). Additional management strategies included de-escalation to ICI monotherapy (n = 5, 8.5%) or discontinued ICI (n = 6, 10.2%). Half of patients treated with corticosteroids demonstrated subjective improvement in symptoms while 75% improved following ICI discontinuation. Four patients underwent rechallenge after a median interruption of 564 days; all (n = 4) demonstrated sicca recurrence.
Conclusions
In this largest cohort to date of ICI-associated sicca syndrome, we confirm frequent improvement with steroids and/or supportive care and suggest a greater than previously appreciated risk of recurrence with rechallenge.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
ORCID-Profile: Meridith L Balbach
Förderung
- NIH HHS
- Department of Defense
- NIH
- DOD
- Susan and Luke Simons Directorship
Zitieren
APA
Balbach, M. L., & Johnson, D. B. (2026). Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome. Cancers, 18(11), 1836. https://doi.org/10.3390/cancers18111836
Vancouver
Balbach ML, Johnson DB. Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome. Cancers. 2026;18(11):1836. doi:10.3390/cancers18111836
BibTeX
@article{Balbach2026,
author = {Balbach, Meridith L and Johnson, Douglas B},
title = {Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1836},
doi = {10.3390/cancers18111836}
}
EUVIMED